Non Alcoholic Fatty Liver Disease clinical trials

Explore recruiting non alcoholic fatty liver disease clinical trials.

Recruiting non alcoholic fatty liver disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Non Alcoholic Fatty Liver Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

17 β-Hydroxysteroid Dehydrogenase type 13 Minimization for the treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults with Nonalcoholic Steatohepatitis

Greece, Italy, Belgium, Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Dasatinib and quercetin, a combination of senolytics to treat fibrotic non-alcoholic fatty liver disease; The TRUTH study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

Effect of orlistat on LIVER fat content in obese subjects with NAFLD and High concEntrAtion of pLasma proneurotensin THrough inhibition of neurotensin secretion and action

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)

Romania, Bulgaria, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Non Alcoholic Fatty Liver Disease trials by city

Non Alcoholic Fatty Liver Disease in Toronto Non Alcoholic Fatty Liver Disease in Vancouver Non Alcoholic Fatty Liver Disease in Montreal Non Alcoholic Fatty Liver Disease in Calgary Non Alcoholic Fatty Liver Disease in Edmonton Non Alcoholic Fatty Liver Disease in Ottawa Non Alcoholic Fatty Liver Disease in Winnipeg Non Alcoholic Fatty Liver Disease in Quebec City Non Alcoholic Fatty Liver Disease in Hamilton Non Alcoholic Fatty Liver Disease in Kitchener Non Alcoholic Fatty Liver Disease in London Non Alcoholic Fatty Liver Disease in Halifax Non Alcoholic Fatty Liver Disease in New York Non Alcoholic Fatty Liver Disease in Los Angeles Non Alcoholic Fatty Liver Disease in Chicago Non Alcoholic Fatty Liver Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease